Edit Symbol List
Don't know the stock symbol? Use the symbol lookup tool.
Alphabetize the sort order of my symbols
Company Description (as filed with the SEC)
We are a biopharmaceutical company developing novel therapies for serious or life-threatening diseases with significant unmet needs. We are leveraging our Molecular Adhesion & Sealant Technology, or MAST, platform, derived from over two decades of clinical, nonclinical and manufacturing experience with purified and non-purified poloxamers, to develop MST-188, our lead product candidate. MST-188 has demonstrated multiple pharmacologic effects that may provide clinical benefit in a wide range of diseases and conditions typically characterized by impaired microvascular blood flow and damaged cell membranes. We recently acquired AIR001, an intermittently nebulized form of sodium nitrite that was being developed to treat pulmonary vascular disorders, and we are in the process of determining the optimal development strategy for this new asset. We are enrolling subjects in EPIC (Evaluation of Purified 188 In Crisis), a pivotal phase 3 study of MST-188 in sickle cell disease. ... More ...